Serena Williams is returning to tennis and bringing the GLP-1 debate with her The former world No.1 has a partnership with Ro and uses the weight-loss drug Zepbound, which is currently being monitored by WADA
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
In a major step forward, the FDA approved the first generic liraglutide for weight loss in August 2025, making these treatments more affordable
Preclinical studies suggest that GLP-1 receptor signaling may also influence intestinal epithelial turnover, oxidative stress, and gut barrier integrity
This gradual approach is designed to help minimize side effects, like nausea or digestive discomfort, and improve how well you tolerate the medication long-term
The liftHD applicator, now available to elevate treatment efficacy and patient throughput, further optimizes body contouring